Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 14/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.37 |
| ▸ | GALR1 | P47211 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405602 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TRPM8GALR2GALR1PDE2A | |
| SCHEMBL15023303 | 0.88 | TRPM8 (0.51) | TRPM8PDE2A | |
| SCHEMBL14407014 | 0.88 | TRPM8 (0.51) | TRPM8PDE2A | |
| SCHEMBL14406942 | 0.86 | L3MBTL1 (0.50) | L3MBTL1TRPM8PDE2A | |
| SCHEMBL14334289 | 0.84 | TRPM8 (0.56) | TRPM8PDE2A | |
| SCHEMBL14334290 | 0.84 | TRPM8 (0.56) | TRPM8PDE2A | |
| Hydrochloric Acid SCHEMBL14333126 | 0.83 | TRPM8 (0.55) | TRPM8PDE2A | |
| Hydrochloric Acid SCHEMBL14333124 | 0.83 | TRPM8 (0.55) | TRPM8PDE2A | |
| SCHEMBL14405600 | 0.82 | TRPM8 (0.45) | TRPM8 | |
| SCHEMBL15034686 | 0.81 | TRPM8 (0.42) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | L3MBTL1 4729/4885TRPM8 1/4885GALR2 368/4885 |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | L3MBTL1 4729/4885TRPM8 1/4885GALR2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.